Skip to main content
ARS Home » Research » Publications at this Location » Publication #131379
Title: RECOMBINANT PARAMYXOVIRUS TYPE 1-AVIAN INFLUENZA-H7 VIRUS AS A VACCINE FOR PROTECTION OF CHICKENS AGAINST INFLUENZA AND NEWCASTLE DISEASE

Author
item Swayne, David
item Suarez, David
item Schultz Cherry, Stacey
item Tumpey, Terrence
item King, Daniel
item NAKAYA, T - MT SANAI SCL OF MED-NY,NY
item PALESE, P - MT SANAI SCL OF MED-NY,NY
item GARCIA-SASTRE, A - MT SANAI SCL OF MED-NY,NY

Submitted to: Avian Diseases
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 10/27/2003
Publication Date: 10/27/2003
Citation: Swayne, D.E., Suarez, D.L., Schultz Cherry, S.L., Tumpey, T., King, D.J., Nakaya, T., Palese, P., Garcia-Sastre, A. 2003. Recombinant Paramyxovirus Type 1-Avian Influenza-H7 Virus As A Vaccine For Protection Of Chickens Against Influenza And Newcastle Disease. Avian Diseases 47(3):1047-1050, 2003.

Interpretive Summary: Vaccines to prevent avian influenza in chickens require injection of each bird. This is very labor intensive and expensive. We have developed a new vaccine based on a commonly used Newcastle disease virus vaccine strain that has been modified through biotechnology to contain the hemagglutinin of H7 avian influenza. This recombinant vaccine can be given by eye drop or rspray administration which is easier and less expensive than injection. In chicken studies, one dose of the vaccine provided partial protection from deadly forms of both Newcastle disease and avian influenza. With two doses of the vaccine, antibodies to both Newcastle disease and avian influenza H7 viruses were detected. This suggests that the recombinant vaccine has the potential for prevention and control of Newcastle disease and avian influenza.

Technical Abstract: Current vaccines to prevent avian influenza rely upon labor-intensive parenteral injection instead of mass immunization by spray or water delivery. A recombinant vaccine (rNDV-AIV-H7) was constructed from Newcastle disease virus [NDV] B1 strain) with insertion of the hemagglutinin (HA) gene from avian influenza virus (AIV) A/chicken/NY/13142-5/94 (H7N2). The recombinant virus was stable and expressed the H7 AIV HA gene. Groups of 2-week-old white Leghorn chickens were vaccinated with transfectant NDV vector (tNDV), rNDV-AIV-H7 or sterile allantoic fluid and were challenged 2 weeks later with viscerotropic velogenic NDV (vvNDV) or highly pathogenic (HP) AIV. The sham-vaccinated birds were not protected from vvNDV or HP AIV challenge. The transfectant NDV vaccine provided 70% protection for NDV challenge but did not protect against AIV challenge. The rNDV-AIV-H7 vaccine provided partial protection (40%) from vvNDV and HP AIV challenge. The serologic response was examined in chickens that received one or two immunizations of the rNDV-AIV-H7 vaccine. Based on hemagglutination inhibition (HI) and ELISA tests, chickens that received vaccine boost seroconverted to AIV H7, but the serologic response was weak in birds that received one vaccination. This demonstrates the potential for NDV for use as a vaccine vector in expressing AIV proteins.